Evotec SE
EVO
Last
$1.54
Day
-1.9%
1y
-60.2%
5y
-98.4%
52w
-63.2%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
—
EMA 21
1.65
EMA 50
1.82
EMA 200
2.53
20d high
-10.3%
5y high
-98.5%
5y range
0th
Positions held
Your positionsEVO isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-12
Hold
avoid
Signal
Sell
Target
$1.68
Stop
$1.47
Stop distance
4.5%
Target vs last
+9.1%
Fundamentals
| Market cap | $557.96M | Enterprise value | $568.17M | Trailing P/E | — | Forward P/E | -8.26 |
| PEG | 1.42 | Price / book | 0.74 | Beta | 1.27 | Dividend yield | 0.00% |
| Revenue growth | -16.2% | Earnings growth | — | Gross margin | 8.5% | Operating margin | -62.3% |
| Profit margin | -27.5% | ROE | -26.1% | ROA | -5.4% | Debt / equity | 0.71 |
| Current ratio | 2.33 | Free cash flow | -$80.99M | Analyst recommendation | none | Mean target | $4.17 |
| 52w high | $4.27 | 52w low | $1.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $143M | $157M | $253M | $164M | $171M | — |
| Op margin | -62.3% | -29.6% | 14.7% | -27.2% | -16.7% | — |
| Net income | -$46.6M | -$122M | $14.6M | -$43.1M | -$43.5M | — |
| Gross margin | -1.1% | -1.0% | 31.0% | -0.0% | 5.0% | — |
| Gross profit | -$1.6M | -$1.6M | $78.5M | -$0.1M | $8.6M | — |
| Operating income | -$89.3M | -$46.4M | $37.2M | -$44.6M | -$28.6M | — |
- Revenue -8% vs prior quarter ($143M vs $157M).
- Gross margin -1.1% (was -1% prior quarter).
- Operating margin compressed to -62.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $788M | $797M | $781M | $751M | — |
| Op margin | -7.1% | -9.9% | -3.4% | 2.8% | — |
| Net income | -$104M | -$196M | -$83.9M | -$176M | — |
| Gross margin | 14.5% | 14.4% | 22.4% | 23.2% | — |
| Gross profit | $114M | $115M | $175M | $174M | — |
| Operating income | -$55.8M | -$78.9M | -$26.6M | $20.9M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Evotec Announces Chief Scientific Officer Transition
2026-09-29 · APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES
2026-09-09 · Evotec Initiates Phase 1 Trial of Potential Smallpox, Mpox Treatment
2026-09-02 · Evotec, Plectonic Launch Research Collaboration on New T-Cell Approaches for Solid Tumors
Price (daily)
Full chart · RSI · MACD · patternsEVO · daily-0.6% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin